Roche haemophilia drug gets fast FDA review in expanded useThe FDA has granted ‘Breakthrough Therapy’ status for Roche’s Hemlibra (emicizumab) for people with haemophilia A without factor Share XRoche haemophilia drug gets fast FDA review in expanded usehttps://pharmaphorum.com/news/roches-haemophilia-drug-breakthrough-expanded-use-fda/
After losing out on two big deals, Sanofi to buy Bioverativ for $11.6bnFrench pharma makes move into haemophilia market. Share XAfter losing out on two big deals, Sanofi to buy Bioverativ for $11.6bnhttps://pharmaphorum.com/news/losing-two-big-deals-sanofi-buys-bioverativ-11-6bn/
‘Cure for hemophilia within reach’ as BioMarin and Spark gene therapies shineWhile clinicians attending the American Society of Hematology meeting in Atlanta this weekend were anticipating a flurry of Share X‘Cure for hemophilia within reach’ as BioMarin and Spark gene therapies shinehttps://pharmaphorum.com/news/cure-hemophilia-within-reach-biomarin-spark-gene-therapies-shine/
Sangamo and new gene therapy partner Pfizer lifted by FDA fast trackSangamo Therapeutics has been granted a fast track designation from the FDA for SB-525, its gene therapy candidate Share XSangamo and new gene therapy partner Pfizer lifted by FDA fast trackhttps://pharmaphorum.com/news/sangamo-new-gene-therapy-partner-pfizer-lifted-fda-fast-track/
